Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Standard
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. / Janni, Wolfgang; Rack, Brigitte; Terstappen, Leon Wmm; Pierga, Jean-Yves; Taran, Florin-Andrei; Fehm, Tanja; Hall, Carolyn; de Groot, Marco; Bidard, Francois-Clement; Friedl, Thomas W P; Fasching, Peter A; Brucker, Sara Y; Pantel, Klaus; Lucci, Anthony.
in: CLIN CANCER RES, Jahrgang 22, Nr. 10, 01.05.2016, S. 2583-93.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
AU - Janni, Wolfgang
AU - Rack, Brigitte
AU - Terstappen, Leon Wmm
AU - Pierga, Jean-Yves
AU - Taran, Florin-Andrei
AU - Fehm, Tanja
AU - Hall, Carolyn
AU - de Groot, Marco
AU - Bidard, Francois-Clement
AU - Friedl, Thomas W P
AU - Fasching, Peter A
AU - Brucker, Sara Y
AU - Pantel, Klaus
AU - Lucci, Anthony
N1 - Copyright © 2015, American Association for Cancer Research.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - PURPOSE: Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTCs) in the peripheral blood of patients with metastatic breast cancer, less evidence is available for the prognostic relevance of CTCs at the time of primary diagnosis.PATIENTS AND METHODS: We conducted a pooled analysis of individual data from 3,173 patients with non-metastatic (Stage I-III) breast cancer from 5 breast cancer institutions. The prevalence and numbers of CTCs were assessed at the time of primary diagnosis with the United States Food and Drug Administration-cleared CellSearch® System (Janssen Diagnostics, LLC). Patient outcomes were analyzed using meta-analytic procedures, univariate log-rank tests, and multivariate Cox proportional hazard regression analyses. The median follow-up duration was 62.8 months.RESULTS: One or more CTCs were detected in 20.2% of the patients. CTC-positive patients had larger tumors, increased lymph node involvement, and a higher histological tumor grade than did CTC-negative patients (all P < 0.002). Multivariate Cox regressions, which included tumor size, nodal status, histological tumor grade, and hormone-receptor and HER2 status, confirmed that the presence of CTCs was an independent prognostic factor for disease-free survival (hazard ratio (HR), 1.82; 95% confidence interval (CI), 1.47 to 2.26), distant disease-free survival (HR, 1.89; 95% CI, 1.49 to 2.40), breast cancer-specific survival (HR, 2.04; 95% CI, 1.52 to 2.75), and overall survival (HR, 1.97; 95% CI, 1.51 to 2.59).CONCLUSION: In patients with primary breast cancer, the presence of CTC was an independent predictor of poor disease-free, overall, breast-cancer-specific, and distant disease-free survival.
AB - PURPOSE: Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTCs) in the peripheral blood of patients with metastatic breast cancer, less evidence is available for the prognostic relevance of CTCs at the time of primary diagnosis.PATIENTS AND METHODS: We conducted a pooled analysis of individual data from 3,173 patients with non-metastatic (Stage I-III) breast cancer from 5 breast cancer institutions. The prevalence and numbers of CTCs were assessed at the time of primary diagnosis with the United States Food and Drug Administration-cleared CellSearch® System (Janssen Diagnostics, LLC). Patient outcomes were analyzed using meta-analytic procedures, univariate log-rank tests, and multivariate Cox proportional hazard regression analyses. The median follow-up duration was 62.8 months.RESULTS: One or more CTCs were detected in 20.2% of the patients. CTC-positive patients had larger tumors, increased lymph node involvement, and a higher histological tumor grade than did CTC-negative patients (all P < 0.002). Multivariate Cox regressions, which included tumor size, nodal status, histological tumor grade, and hormone-receptor and HER2 status, confirmed that the presence of CTCs was an independent prognostic factor for disease-free survival (hazard ratio (HR), 1.82; 95% confidence interval (CI), 1.47 to 2.26), distant disease-free survival (HR, 1.89; 95% CI, 1.49 to 2.40), breast cancer-specific survival (HR, 2.04; 95% CI, 1.52 to 2.75), and overall survival (HR, 1.97; 95% CI, 1.51 to 2.59).CONCLUSION: In patients with primary breast cancer, the presence of CTC was an independent predictor of poor disease-free, overall, breast-cancer-specific, and distant disease-free survival.
U2 - 10.1158/1078-0432.CCR-15-1603
DO - 10.1158/1078-0432.CCR-15-1603
M3 - SCORING: Journal article
C2 - 26733614
VL - 22
SP - 2583
EP - 2593
JO - CLIN CANCER RES
JF - CLIN CANCER RES
SN - 1078-0432
IS - 10
ER -
